Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 16, 2009, Pages 4566-4569

  Chioua, Mourad ^a   Samadi, Abdelouahid ^a   Soriano, Elena ^a   Lozach, Olivier ^b   Meijer, Laurent ^b   Marco Contelles, José ^a  

^a INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

^b Protein Phosphorylation and Human Disease Group   (France)

Author keywords

3,6 Diamino 1H pyrazolo 3,4 b pyridine 5 carbonitriles; Alzheimer's disease; CDK5; GSK 3; Kinase inhibitors; Molecular modelling; Pyrazolo 3,4 b pyridines

Indexed keywords

3,6 DIAMINO 4 PHENYL 1H PYRAZOLO[3,4 B]PYRIDINE 5 CARBONITRILE; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3; PROTEIN; PROTEIN DYRK1A; PROTEIN KINASE INHIBITOR; PYRAZOLO[3,4 B]PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION;

ALZHEIMER DISEASE; BINDING SITES; COMPUTER SIMULATION; CYCLIN-DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIDINES;

EID: 67749116230     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.099     Document Type: Article

References (36)

1. Beutner G.L., Kuethe J.T., Kim M.M., and Yasuda N. J. Org. Chem. 74 (2009) 789
2. 5-Aryl-pyrazolo[3,4-b]pyridines:. Witherington J., Bordas V., Garland S.L., Hickey D.M.B., Ife R.J., Liddle J., Saunders M., Smith D.G., and Ward R.W. Bioorg. Med. Chem. Lett. 13 (2003) 1577
3. 6-aryl-pyrazolo[3,4-b]pyridines:. Witherington J., Bordas V., Gaiba A., Garton N.S., Naylor A., Rawlings A.D., Slingsby B.P., Smith D.G., Takle A.K., and Ward R.W. Bioorg. Med. Chem. Lett. 13 (2003) 3055
4. 6-heteroaryl-pyrazolo[3,4-b]pyridines:. Witherington J., Bordas V., Gaiba A., Garton N.S., Naylor A., Rawlings A.D., Slingsby B.P., Smith D.G., Takle A.K., and Ward R.W. Bioorg. Med. Chem. Lett. 13 (2003) 3059
5. Manning G., Whyte D.B., Martínez R., Hunter T., and Sudarsanam S. Science 298 (2002) 1912
6. Knockaert M., Greengard P., and Meijer L. Trends Pharmacol. Sci. 23 (2002) 417
7. In: Martínez A., Castro A., and Medina M. (Eds). Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors (2006), John Wiley & Sons
8. Woodgett J.R. Trends Biochem. Sci. 16 (1991) 177
9. Ghosh S., and Karin M. Cell 109 (2002) S91
10. Peifer M., and Polakis P. Science 287 (2000) 1606
11. Bhatt R., Xue Y., Berg S., Hellberg S., Ormö M., Nilsson Y., Radesáter A.-C., Jerning E., Markgren P.-O., Borgegàrd T., Nylöf M., Giménez-Cassina A., Hernández F., Lucas J.L., Díaz-Nido J., and Ávila J. J. Biol. Chem. 278 (2003) 45937
12. Malumbres M., Pevarello P., Barbacid M., and Bischoff J.R. Trends Pharmacol. Sci. 29 (2008) 16
13. Oumata N., Bettayeb K., Ferandin Y., Demange L., López-Giral A., Goddard M.-L., Myrianthopoulos V., Mikros E., Flajolet M., Greengard P., Meijer L., and Galons H. J. Med. Chem. 51 (2008) 5229
14. Marco-Contelles J., León R., de los Ríos C., Guglietta A., Terencio J., López M.G., García A.G., and Villarroya M. J. Med. Chem. 49 (2006) 7607 and references cited therein
15. For related studies on dual GSK-3/CDK-1 inhibitors, see:. Logé C., Testard A., Théry V., Lozach O., Blairvacq M., Robert J.-M., Meijer L., and Besson T. Eur. J. Med. Chem. 43 (2008) 1469
16. Schmidt H.W., and Junek H. Monatsch. Chem. 108 (1977) 895
17. Piper J.R., McCaleb G.S., Montgomery J.A., Gaumont Y., and Sirotnak F.M. J. Med. Chem. 29 (1986) 1080
18. Murray T.J., Zimmerman S.C., and Kolotuchin S.V. Tetrahedron 51 (1995) 635
19. Cottis S.G., Clarke P.B., and Tieckelmann H. J. Heterocycl. Chem. 2 (1965) 192
20. Pochat F. Tetrahedron 42 (1986) 4461
21. Abdelrazek F.M., Metwally N.H., and Sobhy N.A. Afinidad 63 (2006) 149
22. El-Mobayed M., Essawy A.-N., El-Bahnasawy A.A., and Amer A.M. Gazz. Chim. Ital. 121 (1991) 209
23. All compounds showed NMR and LC/MS data, in full agreement with their structures, or with the reported data in literature.
24. It is well known that in similar heterocyclic systems, alkyl hydrazines displace chloro atoms through the α-nitrogen, and that aryl hydrazides reacts at the β-nitrogen:. Schmidt P., Eichenberger M., Wilhelm M., and Druey J. Helv. Chim. Acta 42 (1959) 763
25. Hauser M., Peters E., and Tieckelmann H. J. Org. Chem. 25 (1960) 1570
26. 2. Work is in progress to confirm this hypothesis.
27. Doyle M.P., Siegfried B., and Dellaria J.F. J. Org. Chem. 42 (1977) 2426
28. Peinador C., Veiga M.C., Vilar J., and Quintela J.M. Heterocycles 38 (1994) 1299
29. Quintela J.M., and Soto J.L. Anal. Quim. C (1983) 368
30. Álvarez-Insúa A.S., Lora-Tamayo M., and Soto J.L. Anal. Quim. (1970) 1305
31. CDK5/p25, GSK-3α/β, DYRK1A were assayed in the presence of 15 μM ATP as described in references (a), (b) and (c), respectively. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Mandelkow E.-M., Eisenbrand G., and Meijer L. J. Biol. Chem. 276 (2001) 251
32. Primot A., Baratte B., Gompel M., Borgne A., Liabeuf S., Romette J.L., Costantini F., and Meijer L. Protein Exp. Purif. 20 (2000) 394
33. Renault, S.; Lozach, O.; Meijer, L.; Carreaux, F.; Bazureau, J.-P. J. Med. Chem. 2009, in preparation.
34. Aoki M., Iwamoto-Sugai M., Sugiura I., Sasaki C., Hasegawa T., Okumura C., Sugio S., Kohno T., and Matsuzaki T. Acta Crystallogr., Sect. D: Biol. Crystallogr. D56 (2000) 1464
35. Bax B., Carter P.S., Lewid C., Guy A.R., Bridges A., Tanner R., Pettman G., Mannix C., Culbert A.A., Brown M.J.B., Smith D.G., and Reith A.D. Structure (London) 9 (2001) 1143
36. We thank one the reviewers for this suggestion. The preparation of these new molecules needs a new synthetic plan, now in progress in our laboratory, based on the reaction of compound 2 with benzylhydrazine, pyrazole formation, regioselective N-acylation, and N1 deprotection.